文献速递淋巴瘤

BRCA1/2对乳腺癌女性乳房假体相关淋巴瘤发生的影响:毛面假体植入后的分析

BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants.
PubMed 文献 · Blood Adv · 2025-01-01

在520例接受BRCA检测的乳腺癌患者中,BRCA突变者发生乳房假体相关间变性大细胞淋巴瘤(BIA-ALCL)的年龄校正率是非突变者的16倍(95%CI 3.6-76.1,P<.0003)。双侧假体、化疗和放疗与BIA-ALCL无关联。病例对照研究(13例BIA-ALCL匹配39例对照)排除BRCA与BIA-ALCL无关联(P=.0002)。

要点

  • BRCA突变者BIA-ALCL年龄校正发生率是非突变者的16倍(95%CI 3.6-76.1,P<.0003)。
  • 双侧假体(HR 3.9,95%CI 0.4-32.7)、化疗(HR 0.95,95%CI 0.2-4.2)、放疗(HR 0.37,95%CI 0.04-3.1)与BIA-ALCL无关联。
  • 病例对照研究排除BRCA与BIA-ALCL无关联(P=.0002)。

核心结论

  • 本研究将BRCA1/2突变定义为乳腺癌患者发生BIA-ALCL的风险因素。
  • 这些结果将有助于正在接受乳房重建或已植入毛面假体的女性。

研究设计与样本

  • 在大型乳腺癌乳房切除术后植入假体随访人群中,比较发生与未发生BIA-ALCL者的BRCA1/2患病率。
  • 采用Cox回归估计发生BIA-ALCL的风险比(HR)。
  • 另进行病例对照研究,13例BIA-ALCL患者按1:3匹配39例对照。
  • 520例乳腺癌患者接受了BRCA检测。

主要发现

  • BRCA突变者发生BIA-ALCL的年龄校正率是非突变者的16倍(95%CI 3.6-76.1;P<.0003)。
  • 携带双侧假体(HR 3.9;95%CI 0.4-32.7)、化疗(HR 0.95;95%CI 0.2-4.2)、放疗(HR 0.37;95%CI 0.04-3.1)与BIA-ALCL无关联。
  • 病例对照研究采用完全枚举伯努利概率排除BRCA与BIA-ALCL无关联(P=.0002)。

关键数值与推荐

  • BRCA突变者BIA-ALCL年龄校正率是非突变者的16倍(95%CI 3.6-76.1;P<.0003)。
  • 双侧假体HR 3.9(95%CI 0.4-32.7),化疗HR 0.95(95%CI 0.2-4.2),放疗HR 0.37(95%CI 0.04-3.1)。
  • 病例对照研究排除BRCA与BIA-ALCL无关联的P=.0002。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a type of T-cell lymphoma arising near textured breast implants. In a Dutch population, a higher prevalence of BRCA1/2 was found in BIA-ALCL. We analyzed the risk of BIA-ALCL occurrence related to BRCA in a large population of women with implants followed after breast cancer (BC) mastectomy. We compared the prevalence of BRCA1/2 between women from a large cohort of patients with BC who did and did not develop BIA-ALCL after reconstruction with textured implants. Hazard ratios (HRs) of developing BIA-ALCL were estimated using Cox regression. We also conducted a case-control study. Of 520 patients with BC tested for BRCA, the age-adjusted rate of developing BIA-ALCL for women with BRCA was 16 times the rate of BIA-ALCL among women without BRCA (95% confidence interval [CI], 3.6-76.1; P < .0003). Carrying bilateral implants (HR, 3.9; 95% CI, 0.4-32.7), chemotherapy (HR, 0.95; 95% CI, 0.2-4.2), and radiotherapy (HR, 0.37; 95% CI, 0.04-3.1) were not associated with BIA-ALCL. We also conducted a case-control study with 13 BIA-ALCL patients matched 1:3 with 39 controls. We used a complete enumeration of Bernoulli probability to rule out a nonassociation of BRCA with BIA-ALCL (P = .0002). In this study, we defined the role of BRCA1/2 mutations as a risk factor in developing BIA-ALCL in patients with BC. These results will help women undergoing breast reconstruction or with textured implants in place.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ghione P, Mandelker D, Arcila M, et al. BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants. Blood Adv. 2025. PMID: 40512039. doi:10.1182/bloodadvances.2025016810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。